| Literature DB >> 32736172 |
Yaqi Qiu1, Shi Qiu2, Linghui Deng3, Ling Nie4, Lina Gong5, Xinyang Liao5, Xiaonan Zheng5, Kun Jin5, Jiakun Li5, Xiang Tu5, Liangren Liu5, Zhenhua Liu5, Yige Bao5, Jianzhong Ai5, Tianhai Lin5, Lu Yang6, Qiang Wei7.
Abstract
The high potential for cancer relapse has emerged as a crucial challenge of human bladder cancer treatment. To date, those stem-like bladder cancer cells (BCSCs) have been considered as seeds that induce frequent tumor recurrence. However, the cell origin of cancer stem cells (CSCs) is still a controversial issue, due in part to the findings that CSCs not only origin from normal stem cells but also converted from differentiated tumor cells. Here, we describe a biomaterial 3D collagen I gel culture system, where non-tumorigenic cells can obtain tumorigenic potential and revert back into CSCs through the integrin α2β1/PI3K/AKT/NF-κB cascade, resulting in the tumorigenesis in bladder tissues. Furthermore, inhibiting this integrin α2β1/PI3K/AKT/NF-κB signal pathways can significantly impair the tumorigenic capacity of CSCs. Simultaneously, in vivo studies demonstrate that IFN-γ secreted by T cells can trigger those CSCs into dormancy through the IDO/Kyn/AHR/P27 cascade, which elicit chemotherapy resistance and cancer relapse. To address the challenges of suppressing bladder tumor growth and preventing tumor reoccurrence, we use IDO and integrin α2β1 signal pathway inhibitors combine with chemotherapeutic agents to awaken dormant bladder CSCs and inhibit their tumorigenic ability as well as effectively eliminate CSCs. The therapeutic approaches we propose provide new insights for eradicating tumors and reducing bladder cancer relapse after therapy.Entities:
Keywords: Biomaterial; Bladder cancer; Collagen; Tumor dormancy; Tumorigenesis
Mesh:
Substances:
Year: 2020 PMID: 32736172 DOI: 10.1016/j.biomaterials.2020.120217
Source DB: PubMed Journal: Biomaterials ISSN: 0142-9612 Impact factor: 12.479